Navigation Links
Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx
Date:9/18/2013

ditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, vendors and other business partners; the risk that stockholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; Nexavar® (sorafenib) tablets, Kyprolis® (carfilzomib) for Injection and Stivarga® (regorafenib) tablets being the only approved products from which we may obtain revenue; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; supply of Nexavar, Stivarga or Kyprolis; market acceptance and the rate of adoption of Nexavar, Stivarga and Kyprolis; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, Stivarga or Kyprolis; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; and product liability risks; and other risks and uncertainties discussed in Onyx's filings with the Securities and Exchange Commission (the "Commission"), including the "Risk Factors" sections of Onyx's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as the tender offer documents to be filed by Arena Acquisition Corporation, a wholly owned subsidiary of Amgen, and the Solicitation/Recommendation Statement to be filed by Onyx. Onyx undertakes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law. 

Contacts:

Amgen
Ashleigh Koss, 805-313-
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
2. Amgen To Participate At Citis 8th Annual Biotech Conference
3. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
4. Amgen to Highlight New Data at Upcoming ESC Congress 2013
5. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
6. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
7. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
8. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
9. Amgen Announces Webcast of 2013 Second Quarter Financial Results
10. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... and VIENNA , July 31, 2014 ... press conference in New York results ... vaccine against Parkinson,s disease. PD01A is the first therapy against ... clinical testing. The Michael J. Fox Foundation for ... million grant, and presented at the press conference on the ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
(Date:8/1/2014)... The North America Sports Drink Market report ... with analysis and forecast of revenue. The Sports Drink Market ... million in 2012 to $6,243 million by 2018, at a ... the TOC of the North America Sports Drink market report, ... also provides a glimpse of the segmentation in the North ...
(Date:8/1/2014)... The Gerontological Society of America (GSA) ... of aging has chosen Carole B. Lewis, PT, ... 2014 recipient of the Excellence in Rehabilitation of Aging ... to acknowledge outstanding contributions in the field of rehabilitation. ... teaching or patient care, or publications that may include ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , ... to be recognized as a 2014 Best of Home Care ... care providers who rank in the top 50th percentile in ... interviews conducted by Home Care Pulse. , “The Best ... the best of the best!” says Home Care Pulse Founder ...
(Date:8/1/2014)... York City, NY (PRWEB) August 01, 2014 ... for two incomes, and the convenience of processed, microwavable dinners, ... epidemic. Diet Doc does not offer patients a mere quick ... about helping everyone, in any part of the country, get ... that if they offer patients the tools and education on ...
(Date:8/1/2014)... This week marks a significant milestone for ... of paying commissions to its independent distributor sales force. ... 2005 total $1,405,954,677.06. , MonaVie distributors can be found ... commissions in 18 different currencies, including: AUD, EUR, BRL, ... USD, SGD, KRW, TWD, THB and GBP. , ...
Breaking Medicine News(10 mins):Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2
... of Chemistry at Stevens Institute of Technology, recently ... of Michigan. Named in honor of pioneer pharmaceutical ... established to recognize outstanding lifetime achievements in medicinal ... lecture, "Drug Discovery Lessons Learned," was delivered ...
... News) -- Early adolescence is the time that patients with ... pediatric to adult medical care, says a new American Heart ... birth, is the most common type of birth defect. Most ... The majority of children born with a congenital heart ...
... lab tests and imaging can sometimes help diagnose juvenile ... history are the most valuable tools in identifying this ... Journal of the American Academy of Orthopaedic Surgeons ... evaluations and imaging studies meant to screen for juvenile ...
... Turmeric, a bright yellow spice from south Asia belonging ... curries and ancient wisdom suggests that it,s also ... laboratory, Tel Aviv University researchers have discovered that turmeric,s ... highly toxic anti-inflammatory drugs used to fight colon cancer ...
... Amanda Gardner HealthDay Reporter , TUESDAY, March ... or young adult raises your risk of having psychotic ... "This cements much more firmly the reality that ... with the other genetic, environmental and socioeconomic risk factors, ...
... March 2 (HealthDay News) -- A daytime nap of at least ... protect their heart, a new study suggests. The finding comes ... two groups. One group had an hour-long period during the day ... groups were given a mental stress test. Blood pressure and ...
Cached Medicine News:Health News:Stevens' Dr. A. K. Ganguly receives Topliss Award Lecture from University of Michigan 2Health News:Teens With Congenital Heart Disease Need Help Moving to Adult Care 2Health News:Joint pain in children: Is it just a sore knee, or ... ? 2Health News:Fighting cancer at your local Indian restaurant 2Health News:Pot Use in Youth Ups Risk of Psychotic Symptoms in Later Life 2
Standard Deflectable Catheters...
Fixed and steerable lumen diagnostic mapping catheters are offered in a variety of catheter configurations...
The Polaris-DX steerable diagnostic catheter is designed for comfort and ergonomic handling during mapping procedures....
Sophisticated DecaPolar Catheters provide enhanced recording and mapping quality....
Medicine Products: